Sector News

Celgene Corporation Announces the Appointment of Gerald F. Masoudi as Executive Vice President, General Counsel and Corporate Secretary

April 2, 2015
Life sciences
Celgene Corporation (CELG) today announced the appointment of Gerald F. Masoudi as Executive Vice President, General Counsel and Corporate Secretary, effective June 1, 2015. Mr. Masoudi will be responsible for global legal strategy and will serve on the company’s Executive Committee.
 
Mr. Masoudi will succeed Lawrence V. Stein, Celgene’s Executive Vice President, General Counsel and Corporate Secretary since 2012, who is retiring from Celgene following a distinguished business and legal career that also included serving as General Counsel for Wyeth and Genetics Institute and as a partner at the law firm Arnold & Porter.
 
“Larry Stein has served as a valued member of Celgene’s senior leadership team and provided the company important strategic legal counsel,” said Robert J. Hugin, Chairman and CEO of Celgene Corporation. “Celgene is deeply grateful for Larry’s significant contributions during his tenure as General Counsel.”
 
“Jerry brings a wealth of experience to Celgene” said Mr. Hugin. “His deep understanding of regulatory policy and his significant healthcare-related legal expertise will add valuable perspective to our leadership team.”
 
Mr. Masoudi joins Celgene from Covington & Burling LLP, a leading international law firm, where he is a partner and serves as co-chair of the Food and Drug practice group. At Covington, he has advised multinational companies and trade associations on significant litigation, enforcement, regulatory and public policy matters. Before joining Covington, Mr. Masoudi served as Chief Counsel of the U.S. Food and Drug Administration. Before joining FDA, Mr. Masoudi served as Deputy Assistant Attorney General for international, policy and appellate matters in the Antitrust Division of the U.S. Department of Justice. Before his government service, Mr. Masoudi was a trial and litigation partner with the law firm Kirkland & Ellis. Immediately following his graduation from law school, he clerked for Judge Frank H. Easterbrook of the U.S. Court of Appeals for the Seventh Circuit.
 
Mr. Masoudi received his J.D. from The University of Chicago Law School, graduating with high honors and serving on the editorial board of the Law Review. He received his B.A. in economics from Amherst College, Phi Beta Kappa.
 
Source: Celgene

Related News

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]